142 filings
Page 3 of 8
8-K
u3xxl3h
28 Dec 22
Entry into a Material Definitive Agreement
8:15am
8-K
cf4cmd
15 Dec 22
Departure of Directors or Certain Officers
4:09pm
8-K
n0xhk
10 Nov 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:07pm
8-K
9wy 3qaieu
8 Nov 22
Cost Associated with Exit or Disposal Activities
4:06pm
8-K
2g4lc rgpf306k5
3 Nov 22
Akebia Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
4:33pm
8-K
jhlbqi qrw22dp9v
4 Aug 22
Akebia Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
4:14pm
8-K
l04b17y3sadz8z 5wih
18 Jul 22
Entry into a Material Definitive Agreement
5:20pm
8-K
taz9fideodqb3xtj0mn
30 Jun 22
Entry into a Material Definitive Agreement
4:10pm
8-K
x8c4e imax
10 Jun 22
Departure of Directors or Certain Officers
8:00am
8-K
3e8ivt7aivv3ohv
13 May 22
Termination of a Material Definitive Agreement
5:27pm
8-K
z3fuk2x32c6q
9 May 22
Akebia Therapeutics Reports First Quarter 2022 Financial Results and Business Update
4:11pm
8-K
3dk1rdrgcm jrlawx44
7 Apr 22
Entry into a Material Definitive Agreement
4:11pm
8-K
f4117
7 Apr 22
Cost Associated with Exit or Disposal Activities
7:00am
8-K
61wk viv9on1yr1qp
30 Mar 22
Other Events
5:04pm
8-K
nmpgdxwqf3q 7d6
1 Mar 22
Akebia Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Business Highlights
4:04pm
8-K
r756cms
22 Feb 22
Akebia Therapeutics Announces Amendment of License Agreement with Vifor Pharma in Preparation for Potential Vadadustat Launch
8:35am
8-K
35cw5twe0l
24 Jan 22
Departure of Directors or Certain Officers
4:42pm
8-K/A
r1a fpt010fpm
15 Dec 21
Departure of Directors or Certain Officers
5:20pm
8-K
mm3sdid8a 8xzi
4 Nov 21
Akebia Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Milestones
8:10am
8-K
dmvx39un
1 Nov 21
Departure of Directors or Certain Officers
5:01pm